Tuning In To Patients

Remix™ designs clinical programs with the same spirit of discovery and determination that emanates from our research labs. Our clinical trials are built to rapidly understand and evaluate how our medicines may help patients. If you are a patient or caretaker interested in a Remix clinical trial, please talk with your doctor about ways to be involved.

Remix is advancing a broad pipeline of RNA processing modulators across Oncology and Neurodegeneration.

Active Trials

REM-422 is a MYB mRNA Degrader.

MYB is a transcription factor known to be an oncogenic driver of multiple solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC) and acute myeloid leukemia/myelodysplastic syndromes (AML/MDS). REM-422 is a potent, selective oral small molecule that induces the reduction of MYB mRNA and protein expression, thereby providing antitumor activity in preclinical MYB-dependent human tumor models.

Clinical Site Map


Duarte, CA 91010
City of Hope (AML)
Principal Investigator:
Anthony S. Stein, MD


Jacksonville, FL 32224
Mayo Clinic (AML)
Principal Investigator:
James M. Foran, MD


Boston, MA 02215
Dana Farber Cancer Research Institute (ACC)
Principal Investigator:
Glenn Hanna, MD


Ann Arbor, MI 48109
University of Michigan Rogel Cancer Center (ACC)
Principal Investigator:
Paul L Swiecicki, MD

New York

New York, NY 10065
Memorial Sloan Kettering Cancer Center (ACC)
Principal Investigator:
Alan L Ho, MD, PhD
New York, NY 10065
Memorial Sloan Kettering Cancer Center (AML)
Principal Investigator:
Eytan M. Stein, MD


Nashville, TN 37203
Sarah Cannon Research Institute (ACC)
Principal Investigator:
Meredith McKean, MD


Houston, TX 77030
MD Anderson Cancer Center (ACC)
Principal Investigator:
Courtney D. DiNardo, MD

Patient Mural

Patients are at the forefront of our thinking. Every day we walk into work, we pass by a mural of friends and family that have been impacted by disease to remind ourselves of our dedication. Their faces inspire us and fuel our passion to urgently deliver new medicines.

Patient Resources

Remix provides patient access to our investigational products in well-controlled clinical trials. We do not have an expanded access program.